-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Estrogen receptor (ER)-positive endometrial carcinoma (EC) is characterized by PI3K pathway mutations in about 90% of cases and about 80% of cases carrying receptor tyrosine kinase (RTK)/RAS/β-catenin (CTNNB1) pathway variants
The researchers speculate that the combined application of the aromatase inhibitor letrozole and the CDK4/6 inhibitor abemaciclib may benefit significantly in
The study is a phase II, two-stage clinical trial designed to evaluate the efficacy and safety
As of December 3, 2021, a total of 30 patients have received the study treatment; Fifteen (50%) patients had previously received hormone therapy
The most common treatment-related adverse effects of grade 3 and above are neutropenia (20%) and anemia (17%)
Exploratory tumor analysis revealed several candidate predictors associated with treatment response mechanisms (CTNNB1, KRAS and CDKN2A mutations, TP53 mutations [associated with no response to treatment]) that require independent validation
Overall, the findings show that letrozole plus Abbesilil exhibits encouraging sustained therapeutic activity
Original Source:
Panagiotis A.